Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September

This article was originally published in The Pink Sheet Daily

Executive Summary

After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.

You may also be interested in...



Prevnar 13 Advisory Committee Review Moved Back To November

Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.

Prevnar 13 Advisory Committee Review Moved Back To November

Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.

Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas

FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel